News and Announcements
Cellmid Limited (ASX:CDY) Signs Major Japanese Distribution Agreement
- Published September 20, 2013 10:28AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Agreement signed for the sale of 30,000 units of Cellmid’s FGF-5 inhibitor lotions
- Significant step in increasing Japanese sales
- Building strong relationship with customers with the view to launch new products
SYDNEY, Friday, 20 September 2013: Cellmid Limited (ASX: CDY) is pleased to advise that it has signed an agreement with Natural Garden Co Ltd (Chiba, Japan), one of the largest Japanese private direct marketing companies, for the supply of 30,000 units of the Company’s FGF-5 inhibitor hair growth lotions.
Under the terms, Cellmid will supply Natural Garden with a minimum of 30,000 units of Andeprong S, one of the newly acquired and successful Japanese brands, during the 12 months from November 2013. Supply price will depend on the quantity of individual orders, which must be at a minimum of 10,000 units each.
To read the full ASX Release please click on the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
